{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:14:23Z","timestamp":1787004863087,"version":"build-2736575974"},"reference-count":106,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hamostaseologie"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Second-generation thrombopoietin receptor agonists (TPO-RAs), romiplostim, eltrombopag, and avatrombopag, have been proved to be significant stimulators of megakaryopoiesis and, in the last decade, they have been incorporated in the treatment options against refractory immune thrombocytopenia in children and adults that do not respond to conventional therapy. Additionally, given their beneficial impact on hematopoiesis, they have successfully been applied in cases of non-immune thrombocytopenia, such as aplastic anemia, HCV-related thrombocytopenia, chronic liver disease, and most recently acute radiation syndrome. During the past years, a wide variety of clinical studies have been performed, in regard to the use of TPO-RAs in various thrombocytopenic settings, such as malignant hematology and hematopoietic stem cell transplantation, hereditary thrombocytopenias, and chemotherapy-treated patients with solid organ tumors. Although data indicate that TPO-RAs may be an effective and safe option for managing disease- or treatment-related thrombocytopenia in these patients, further research is needed to determine their efficacy and safety in these settings. Furthermore, recent studies have highlighted novel properties of TPO-RAs that render them as potential treatment candidates for reducing tumor burden or fighting infections. Herein, we discuss the potential novel applications of TPO-RAs and focus on data regarding their efficacy and safety in these contexts.<\/jats:p>","DOI":"10.1055\/a-2250-9369","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T20:16:53Z","timestamp":1710793013000},"page":"465-481","source":"Crossref","is-referenced-by-count":3,"title":["Novel Perspectives on Thrombopoietin Receptor Agonists Applications"],"prefix":"10.1055","volume":"45","author":[{"given":"Christos","family":"Stafylidis","sequence":"additional","affiliation":[{"name":"Hematology Unit, First Department of Internal Medicine, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Vlachopoulou","sequence":"additional","affiliation":[{"name":"Hematology Unit, First Department of Internal Medicine, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavroula","family":"Syriopoulou","sequence":"additional","affiliation":[{"name":"Hematology Unit, First Department of Internal Medicine, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevastianos","family":"Chatzidavid","sequence":"additional","affiliation":[{"name":"Hematology Unit, First Department of Internal Medicine, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora-Athina","family":"Viniou","sequence":"additional","affiliation":[{"name":"Hematology Unit, First Department of Internal Medicine, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,3,18]]},"reference":[{"issue":"02","key":"ref1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjh.12772","article-title":"Thrombopoietin from beginning to end","volume":"165","author":"I S Hitchcock","year":"2014","journal-title":"Br J Haematol"},{"issue":"01","key":"ref2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12185-013-1382-0","article-title":"The biology of thrombopoietin and thrombopoietin receptor agonists","volume":"98","author":"D J Kuter","year":"2013","journal-title":"Int J Hematol"},{"issue":"04","key":"ref3","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1053\/j.seminhematol.2019.09.001","article-title":"Mechanisms and therapeutic prospects of thrombopoietin receptor agonists","volume":"56","author":"J Bussel","year":"2019","journal-title":"Semin Hematol"},{"issue":"06","key":"ref4","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3324\/haematol.2018.212845","article-title":"Thrombopoietin receptor agonists: ten years later","volume":"104","author":"W Ghanima","year":"2019","journal-title":"Haematologica"},{"issue":"03","key":"ref5","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/j.seminhematol.2010.02.005","article-title":"Biology and chemistry of thrombopoietic agents","volume":"47","author":"D J Kuter","year":"2010","journal-title":"Semin Hematol"},{"issue":"12","key":"ref6","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.3324\/haematol.2016.146746","article-title":"Revealing eltrombopag's promotion of human megakaryopoiesis through AKT\/ERK-dependent pathway activation","volume":"101","author":"C A Di Buduo","year":"2016","journal-title":"Haematologica"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"906036","DOI":"10.3389\/fphar.2022.906036","article-title":"Exploring the potential of eltrombopag: room for more?","volume":"13","author":"F Tarantini","year":"2022","journal-title":"Front Pharmacol"},{"issue":"13","key":"ref8","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1007\/s40265-021-01575-1","article-title":"Hetrombopag: first approval","volume":"81","author":"Y Y Syed","year":"2021","journal-title":"Drugs"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"112","DOI":"10.5045\/br.2022.2022038","article-title":"Recent advances in treatments of adult immune thrombocytopenia","volume":"57","author":"D S Kim","year":"2022","journal-title":"Blood Res"},{"issue":"30","key":"ref10","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.3748\/wjg.v28.i30.4061","article-title":"Thrombocytopenia in chronic liver disease: physiopathology and new therapeutic strategies before invasive procedures","volume":"28","author":"P Gallo","year":"2022","journal-title":"World J Gastroenterol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"113905","DOI":"10.1016\/j.biopha.2022.113905","article-title":"Myelodysplastic neoplasms: an overview on diagnosis, risk-stratification, molecular pathogenesis, and treatment","volume":"156","author":"F K Marques","year":"2022","journal-title":"Biomed Pharmacother"},{"issue":"05","key":"ref12","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1600-0609.2009.01299.x","article-title":"Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes","volume":"83","author":"J Neukirchen","year":"2009","journal-title":"Eur J Haematol"},{"issue":"03","key":"ref13","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JCO.2009.24.7999","article-title":"Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia","volume":"28","author":"H Kantarjian","year":"2010","journal-title":"J Clin Oncol"},{"issue":"17","key":"ref14","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood-2010-03-274753","article-title":"Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy","volume":"116","author":"H M Kantarjian","year":"2010","journal-title":"Blood"},{"issue":"02","key":"ref15","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3109\/10428194.2012.713477","article-title":"A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine","volume":"54","author":"P L Greenberg","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1756-8722-5-71","article-title":"A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide","volume":"5","author":"E S Wang","year":"2012","journal-title":"J Hematol Oncol"},{"issue":"12","key":"ref17","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/cncr.28663","article-title":"Results of a randomized, double-blind study of romiplostim versus placebo in patients with low\/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia","volume":"120","author":"A Giagounidis","year":"2014","journal-title":"Cancer"},{"issue":"03","key":"ref18","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1016\/S2352-3026(18)30016-4","article-title":"Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial","volume":"5","author":"H M Kantarjian","year":"2018","journal-title":"Lancet Haematol"},{"issue":"09","key":"ref19","first-page":"CD009883","article-title":"Thrombopoietin mimetics for patients with myelodysplastic syndromes","volume":"9","author":"H Dodillet","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"582686","DOI":"10.3389\/fonc.2020.582686","article-title":"Safety and efficacy of eltrombopag and romiplostim in myelodysplastic syndromes: a systematic review and meta-analysis","volume":"10","author":"F Meng","year":"2020","journal-title":"Front Oncol"},{"issue":"05","key":"ref21","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/ejh.12383","article-title":"A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine","volume":"93","author":"T Svensson","year":"2014","journal-title":"Eur J Haematol"},{"issue":"03","key":"ref22","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3026(17)30012-1","article-title":"Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial","volume":"4","author":"E N Oliva","year":"2017","journal-title":"Lancet Haematol"},{"issue":"12","key":"ref23","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.3324\/haematol.2020.249995","article-title":"Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome","volume":"105","author":"A Vicente","year":"2020","journal-title":"Haematologica"},{"issue":"01","key":"ref24","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1158\/1078-0432.CCR-22-1457","article-title":"Lenalidomide and eltrombopag for treatment of low- or intermediate-risk myelodysplastic syndrome: result of a phase II clinical trial","volume":"29","author":"J D Gonzalez-Lugo","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"01","key":"ref25","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/S2352-3026(17)30228-4","article-title":"Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial","volume":"5","author":"M Mittelman","year":"2018","journal-title":"Lancet Haematol"},{"issue":"25","key":"ref26","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1182\/blood-2018-06-855221","article-title":"Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia","volume":"132","author":"M Dickinson","year":"2018","journal-title":"Blood"},{"issue":"02","key":"ref27","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bjh.18389","article-title":"Phase Ib study of eltrombopag and azacitidine in patients with high-risk myelodysplastic syndromes and related disorders (the ELASTIC study)","volume":"199","author":"A Sternberg","year":"2022","journal-title":"Br J Haematol"},{"issue":"09","key":"ref28","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1080\/10428194.2019.1576873","article-title":"A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure","volume":"60","author":"M Swaminathan","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"08","key":"ref29","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1080\/10428194.2020.1751841","article-title":"A sequential two-stage dose escalation study of eltrombopag in patients with myelodysplastic syndrome and thrombocytopenia after hypomethylating agent failure","volume":"61","author":"V H Duong","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"24","key":"ref30","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1182\/blood.2019000478","article-title":"Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag","volume":"133","author":"T Winkler","year":"2019","journal-title":"Blood"},{"issue":"18","key":"ref31","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1182\/blood-2009-04-219493","article-title":"Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"114","author":"B Will","year":"2009","journal-title":"Blood"},{"issue":"03","key":"ref32","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.leukres.2010.06.029","article-title":"Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome","volume":"35","author":"I Mavroudi","year":"2011","journal-title":"Leuk Res"},{"issue":"09","key":"ref33","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.leukres.2010.02.005","article-title":"Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag","volume":"34","author":"C L Erickson-Miller","year":"2010","journal-title":"Leuk Res"},{"issue":"05","key":"ref34","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/leu.2012.310","article-title":"Eltrombopag inhibition of acute myeloid leukemia cell survival does not depend on c-Mpl expression","volume":"27","author":"M Sugita","year":"2013","journal-title":"Leukemia"},{"issue":"02","key":"ref35","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1182\/blood-2011-12-399667","article-title":"Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation","volume":"120","author":"M Roth","year":"2012","journal-title":"Blood"},{"issue":"04","key":"ref36","doi-asserted-by":"crossref","first-page":"e0126691","DOI":"10.1371\/journal.pone.0126691","article-title":"Eltrombopag modulates reactive oxygen species and decreases acute myeloid leukemia cell survival","volume":"10","author":"A Kalota","year":"2015","journal-title":"PLoS One"},{"issue":"05","key":"ref37","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.3892\/ijo.2015.3180","article-title":"The eltrombopag antitumor effect on hepatocellular carcinoma","volume":"47","author":"T Kurokawa","year":"2015","journal-title":"Int J Oncol"},{"issue":"458","key":"ref38","doi-asserted-by":"crossref","first-page":"eaas9563","DOI":"10.1126\/scitranslmed.aas9563","article-title":"Thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag","volume":"10","author":"Y R Kao","year":"2018","journal-title":"Sci Transl Med"},{"issue":"14","key":"ref39","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.18632\/oncotarget.28000","article-title":"Eltrombopag and its iron chelating properties in pediatric acute myeloid leukemia","volume":"12","author":"M Argenziano","year":"2021","journal-title":"Oncotarget"},{"issue":"01","key":"ref40","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1186\/s12885-020-07668-6","article-title":"Eltrombopag inhibits the proliferation of Ewing sarcoma cells via iron chelation and impaired DNA replication","volume":"20","author":"T Waters","year":"2020","journal-title":"BMC Cancer"},{"issue":"04","key":"ref41","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3390\/ph15040440","article-title":"Eltrombopag as an allosteric inhibitor of the METTL3-14 complex affecting the m6A methylation of RNA in acute myeloid leukemia cells","volume":"15","author":"J H Lee","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"03","key":"ref42","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S2352-3026(18)30231-X","article-title":"Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study","volume":"6","author":"N Frey","year":"2019","journal-title":"Lancet Haematol"},{"issue":"10","key":"ref43","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1016\/S2352-3026(15)00149-0","article-title":"Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1\/2 trial","volume":"2","author":"U Platzbecker","year":"2015","journal-title":"Lancet Haematol"},{"issue":"S 01","key":"ref44","doi-asserted-by":"crossref","first-page":"6142","DOI":"10.1182\/blood-2022-167000","article-title":"Epag 2015: A Phase II randomized placebo-controlled study to assess the impact on outcome of eltrombopag administered to elderly patients with acute myeloid leukemia receiving induction chemotherapy: a French Innovative Leukemia Organization (FILO) study","volume":"140","author":"A Pigneux","year":"2022","journal-title":"Blood"},{"issue":"S 01","key":"ref45","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1182\/blood-2019-132178","article-title":"A single arm, phase II study of eltrombopag to enhance platelet count recovery in older patients with acute myeloid leukemia (AML) undergoing remission induction therapy","volume":"134","author":"S Mukherjee","year":"2019","journal-title":"Blood"},{"issue":"09","key":"ref46","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1080\/10428194.2020.1762878","article-title":"A novel PrECOG (PrE0901) dose-escalation trial using eltrombopag: enhanced platelet recovery during consolidation therapy in acute myeloid leukemia","volume":"61","author":"S A Strickland","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"701539","DOI":"10.3389\/fonc.2021.701539","article-title":"A real-world observation of eltrombopag and recombinant human thrombopoietin (rhTPO) in lymphoma patients with chemotherapy induced thrombocytopenia","volume":"11","author":"Q Zhu","year":"2021","journal-title":"Front Oncol"},{"issue":"11","key":"ref48","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.3324\/haematol.2020.260125","article-title":"The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis","volume":"106","author":"M Shoukier","year":"2021","journal-title":"Haematologica"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13045-015-0136-2","article-title":"The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma","volume":"8","author":"J Y Jeong","year":"2015","journal-title":"J Hematol Oncol"},{"issue":"S 02","key":"ref50","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/S0049-3848(14)50011-4","article-title":"Thrombocytopenia in cancer patients","volume":"133","author":"H A Liebman","year":"2014","journal-title":"Thromb Res"},{"issue":"05","key":"ref51","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/17474086.2021.1924053","article-title":"Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia","volume":"14","author":"H Al-Samkari","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"970978","DOI":"10.3389\/fphar.2022.970978","article-title":"Avatrombopag for the treatment of thrombocytopenia induced by chemotherapy in patients with solid tumors: a multicenter, open-label, single-arm trial","volume":"13","author":"Y Cui","year":"2022","journal-title":"Front Pharmacol"},{"issue":"05","key":"ref53","first-page":"1217","article-title":"Romiplostim for management of chemotherapy-induced thrombocytopenia","volume":"22","author":"R Parameswaran","year":"2014","journal-title":"Support Care Cancer"},{"issue":"04","key":"ref54","doi-asserted-by":"crossref","first-page":"E86","DOI":"10.1002\/ajh.25022","article-title":"A single center experience with romiplostim for the management of chemotherapy-induced thrombocytopenia","volume":"93","author":"J Miao","year":"2018","journal-title":"Am J Hematol"},{"issue":"04","key":"ref55","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.3324\/haematol.2017.180166","article-title":"The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors","volume":"103","author":"H Al-Samkari","year":"2018","journal-title":"Haematologica"},{"issue":"31","key":"ref56","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1200\/JCO.18.01931","article-title":"Romiplostim treatment of chemotherapy-induced thrombocytopenia","volume":"37","author":"G A Soff","year":"2019","journal-title":"J Clin Oncol"},{"issue":"19","key":"ref57","doi-asserted-by":"crossref","first-page":"e1799","DOI":"10.1212\/WNL.0000000000008440","article-title":"Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma: the PLATUM trial","volume":"93","author":"E Le Rhun","year":"2019","journal-title":"Neurology"},{"issue":"04","key":"ref58","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.3324\/haematol.2020.251900","article-title":"A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies","volume":"106","author":"H Al-Samkari","year":"2021","journal-title":"Haematologica"},{"issue":"12","key":"ref59","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1002\/ajh.26338","article-title":"Thrombopoietin level predicts response to treatment with romiplostim in chemotherapy-induced thrombocytopenia","volume":"96","author":"A B Song","year":"2021","journal-title":"Am J Hematol"},{"issue":"03","key":"ref60","doi-asserted-by":"crossref","first-page":"e12701","DOI":"10.1002\/rth2.12701","article-title":"Romiplostim for chemotherapy-induced thrombocytopenia: efficacy and safety of extended use","volume":"6","author":"C R Wilkins","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"08","key":"ref61","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1080\/09537104.2022.2117293","article-title":"Romiplostim for PARP inhibitor-induced thrombocytopenia in solid tumor malignancies","volume":"33","author":"A Z Cheloff","year":"2022","journal-title":"Platelets"},{"issue":"10","key":"ref62","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1185\/03007995.2010.510051","article-title":"A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin\/paclitaxel for advanced solid tumors","volume":"26","author":"A Kellum","year":"2010","journal-title":"Curr Med Res Opin"},{"issue":"01","key":"ref63","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/cam4.326","article-title":"Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study","volume":"4","author":"E S Winer","year":"2015","journal-title":"Cancer Med"},{"issue":"06","key":"ref64","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s12185-017-2319-9","article-title":"Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study","volume":"106","author":"E S Winer","year":"2017","journal-title":"Int J Hematol"},{"issue":"07","key":"ref65","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1080\/09537104.2022.2026910","article-title":"Effect of avatrombopag in the management of severe and refractory chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors","volume":"33","author":"Y Gao","year":"2022","journal-title":"Platelets"},{"issue":"03","key":"ref66","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/S2352-3026(22)00001-1","article-title":"Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"H Al-Samkari","year":"2022","journal-title":"Lancet Haematol"},{"issue":"01","key":"ref67","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jtha.2023.09.031","article-title":"Management of chemotherapy-induced thrombocytopenia: guidance from the ISTH Subcommittee on Hemostasis and Malignancy","volume":"22","author":"G Soff","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref68","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1053\/bbmt.2001.v7.pm11302549","article-title":"Secondary failure of platelet recovery after hematopoietic stem cell transplantation","volume":"7","author":"B Bruno","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"issue":"02","key":"ref69","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s12288-019-01194-7","article-title":"Eltrombopag: role in cytopenias following hematopoietic stem cell transplantation","volume":"36","author":"R Vasudevan Nampoothiri","year":"2020","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"08","key":"ref70","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jtct.2021.04.007","article-title":"Standardizing definitions of hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the American Society for Transplantation and Cellular Therapy","volume":"27","author":"M A Kharfan-Dabaja","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"07","key":"ref71","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/bmt.2010.218","article-title":"Delayed platelet recovery after allogeneic transplantation: a predictor of increased treatment-related mortality and poorer survival","volume":"46","author":"P Ram\u00edrez","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"01","key":"ref72","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1177\/1078155215612240","article-title":"Evaluation of romiplostim for the treatment of secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant patients","volume":"23","author":"M E Hartranft","year":"2017","journal-title":"J Oncol Pharm Pract"},{"issue":"03","key":"ref73","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ejh.13132","article-title":"Usefulness of thrombopoietin receptor agonists for persistent clinically relevant thrombocytopenia after allogeneic stem cell transplantation","volume":"101","author":"A Bosch-Vilaseca","year":"2018","journal-title":"Eur J Haematol"},{"issue":"08","key":"ref74","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/s41409-019-0435-2","article-title":"Eltrombopag is an effective and safe therapy for refractory thrombocytopenia after haploidentical hematopoietic stem cell transplantation","volume":"54","author":"H Fu","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"07","key":"ref75","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.bbmt.2019.01.027","article-title":"Eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation","volume":"25","author":"C Yuan","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"08","key":"ref76","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41409-019-0442-3","article-title":"Eltrombopag for post-transplant cytopenias due to poor graft function","volume":"54","author":"S Marotta","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"09","key":"ref77","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.bbmt.2019.05.023","article-title":"Thrombopoietin receptor agonists for severe thrombocytopenia after allogeneic stem cell transplantation: experience of the Spanish group of hematopoietic stem cell transplant","volume":"25","author":"L Bento","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/2040620720961910","article-title":"Rescue treatment with eltrombopag in refractory cytopenias after allogeneic stem cell transplantation","volume":"11","author":"S Aydin","year":"2020","journal-title":"Ther Adv Hematol"},{"issue":"11","key":"ref79","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1007\/s00277-020-04106-2","article-title":"Eltrombopag treatment promotes platelet recovery and reduces platelet transfusion for patients with post-transplantation thrombocytopenia","volume":"99","author":"F Gao","year":"2020","journal-title":"Ann Hematol"},{"issue":"01","key":"ref80","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41409-020-0975-5","article-title":"Therapy of posttransplant poor graft function with eltrombopag","volume":"56","author":"K Halahleh","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"02","key":"ref81","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s12185-021-03153-3","article-title":"Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study","volume":"114","author":"S Giammarco","year":"2021","journal-title":"Int J Hematol"},{"issue":"02","key":"ref82","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00277-021-04706-6","article-title":"Eltrombopag in the treatment of patients with persistent thrombocytopenia after haploidentical peripheral blood stem cell transplantation: a single-center experience","volume":"101","author":"F Yan","year":"2022","journal-title":"Ann Hematol"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/20406207221127532","article-title":"Avatrombopag for the treatment of thrombocytopenia post hematopoietic stem-cell transplantation","volume":"13","author":"M Zhou","year":"2022","journal-title":"Ther Adv Hematol"},{"issue":"03","key":"ref84","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood.2019000358","article-title":"Romiplostim in patients undergoing hematopoietic stem cell transplantation: results of a phase 1\/2 multicenter trial","volume":"135","author":"R Peffault de Latour","year":"2020","journal-title":"Blood"},{"issue":"05","key":"ref85","doi-asserted-by":"crossref","first-page":"430.e1","DOI":"10.1016\/j.jtct.2021.02.004","article-title":"Eltrombopag for post-transplantation thrombocytopenia: results of phase II randomized, double-blind, placebo-controlled trial","volume":"27","author":"S Ahmed","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"01","key":"ref86","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3390\/cells9010031","article-title":"The thrombopoietin receptor agonist eltrombopag inhibits human cytomegalovirus replication via iron chelation","volume":"9","author":"J U Vogel","year":"2019","journal-title":"Cells"},{"issue":"09","key":"ref87","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.3390\/ijms22094330","article-title":"Role of thrombopoietin receptor agonists in inherited thrombocytopenia","volume":"22","author":"J M Bastida","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"26","key":"ref88","doi-asserted-by":"crossref","first-page":"5832","DOI":"10.1182\/blood-2010-08-304725","article-title":"Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations","volume":"116","author":"A Pecci","year":"2010","journal-title":"Blood"},{"issue":"11","key":"ref89","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-09-602573","article-title":"Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome\/X-linked thrombocytopenia","volume":"126","author":"A J Gerrits","year":"2015","journal-title":"Blood"},{"issue":"03","key":"ref90","doi-asserted-by":"crossref","first-page":"820","DOI":"10.3324\/haematol.2019.223966","article-title":"Eltrombopag for the treatment of inherited thrombocytopenias: a phase II clinical trial","volume":"105","author":"C Zaninetti","year":"2020","journal-title":"Haematologica"},{"issue":"02","key":"ref91","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/bjh.17174","article-title":"Efficacy of romiplostim in treatment of thrombocytopenia in children with Wiskott-Aldrich syndrome","volume":"192","author":"A Khoreva","year":"2021","journal-title":"Br J Haematol"},{"issue":"04","key":"ref92","first-page":"e4361","article-title":"Thrombopoietin receptor agonists: Can these be the future answer to the deadly thrombocytopenia in dengue fever?","volume":"11","author":"S Roy","year":"2019","journal-title":"Cureus"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"100624","DOI":"10.1016\/j.eclinm.2020.100624","article-title":"Investigation of the efficacy and safety of eltrombopag to correct thrombocytopenia in moderate to severe dengue patients - a phase II randomized controlled clinical trial","volume":"30","author":"S Chakraborty","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"03","key":"ref94","doi-asserted-by":"crossref","first-page":"32","DOI":"10.53339\/aimdr.2022.8.3.5","article-title":"Efficacy and safety of low dose, short course eltrombopag in management of DF and DHF","volume":"8","author":"M M Rahman","year":"2022","journal-title":"Annals of International Medical and Dental Research"},{"issue":"01","key":"ref95","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1658-3876(11)50062-7","article-title":"Romiplostim reverts the thrombocytopenia in dengue hemorrhagic fever","volume":"4","author":"S M Rodr\u00edguez-Mejorada","year":"2011","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"04","key":"ref96","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s00284-021-02386-z","article-title":"Identification of eltrombopag as a repurposing drug against Staphylococcus epidermidis and its biofilms","volume":"78","author":"J Zhu","year":"2021","journal-title":"Curr Microbiol"},{"issue":"11","key":"ref97","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.3390\/antibiotics10111372","article-title":"Repurposing eltrombopag for multidrug resistant Staphylococcus aureus infections","volume":"10","author":"H Lee","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"ref98","doi-asserted-by":"crossref","first-page":"790686","DOI":"10.3389\/fmicb.2021.790686","article-title":"Repurposing eltrombopag as an antimicrobial agent against methicillin-resistant Staphylococcus aureus.","volume":"12","author":"P She","year":"2022","journal-title":"Front Microbiol"},{"issue":"09","key":"ref99","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/imj.13181","article-title":"Cytomegalovirus-associated thrombocytopenia treated with thrombopoietin receptor agonist","volume":"46","author":"J D Simpson","year":"2016","journal-title":"Intern Med J"},{"issue":"10","key":"ref100","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3390\/v12101067","article-title":"Identification of modulators of HIV-1 proviral transcription from a library of FDA-approved pharmaceuticals","volume":"12","author":"G C Sampey","year":"2020","journal-title":"Viruses"},{"issue":"04","key":"ref101","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/mmy\/myz077","article-title":"Repurposing the thrombopoietin receptor agonist eltrombopag as an anticryptococcal agent","volume":"58","author":"H T Ko","year":"2020","journal-title":"Med Mycol"},{"issue":"06","key":"ref102","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/SMJ.0b013e3181ddd571","article-title":"Acute radiation syndrome: assessment and management","volume":"103","author":"E H Donnelly","year":"2010","journal-title":"South Med J"},{"issue":"02","key":"ref103","doi-asserted-by":"crossref","first-page":"190","DOI":"10.2174\/1389201016666150826125331","article-title":"Mitigative effects of a combination of multiple pharmaceutical drugs on the survival of mice exposed to lethal ionizing radiation","volume":"17","author":"T Hirouchi","year":"2015","journal-title":"Curr Pharm Biotechnol"},{"issue":"01","key":"ref104","doi-asserted-by":"crossref","first-page":"10659","DOI":"10.1038\/s41598-018-29013-5","article-title":"The thrombopoietin mimetic romiplostim leads to the complete rescue of mice exposed to lethal ionizing radiation","volume":"8","author":"M Yamaguchi","year":"2018","journal-title":"Sci Rep"},{"key":"ref105","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.freeradbiomed.2019.03.023","article-title":"Diverse functions of the thrombopoietin receptor agonist romiplostim rescue individuals exposed to lethal radiation","volume":"136","author":"M Yamaguchi","year":"2019","journal-title":"Free Radic Biol Med"},{"issue":"01","key":"ref106","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/09553002.2019.1625488","article-title":"Pharmacodynamics of romiplostim alone and in combination with pegfilgrastim on acute radiation-induced thrombocytopenia and neutropenia in non-human primates","volume":"96","author":"K Wong","year":"2020","journal-title":"Int J Radiat Biol"}],"container-title":["H\u00e4mostaseologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2250-9369.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T23:31:06Z","timestamp":1767915066000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2250-9369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,18]]},"references-count":106,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2026,1,8]]},"published-print":{"date-parts":[[2025,12]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2250-9369","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-9355","2567-5761"],"issn-type":[{"value":"0720-9355","type":"print"},{"value":"2567-5761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,18]]}}}